Table 1—

Characteristics of enrolled population and rate of study completion

Treatment sequence
CSII to MDIMDI to CSIIAll subjects
n5050100
Age (years)41.7 ± 11.144.2 ± 11.043.0 ± 11.1
Sex (%)
    Male19 (38)18 (36)37 (37)
    Female31 (62)32 (64)63 (63)
Race (%)
    Caucasian48 (96)48 (96)96 (96)
    Hispanic2 (4)1 (2)3 (3)
    Asian0 (0)1 (2)1 (1)
BMI (kg/m2)27.1 ± 4.126.7 ± 4.026.9 ± 4.0
HbA1c at screening (%)7.5 ± 0.87.4 ± 0.87.5 ± 0.8
Duration of diabetes (years)19.7 ± 11.323.9 ± 12.321.8 ± 11.9
Daily insulin dose (IU/kg)0.54 ± 0.23 (n = 45)0.54 ± 0.21 (n = 50)0.54 ± 0.22 (n = 95)
    Basal0.27 ± 0.100.29 ± 0.140.28 ± 0.12
    Bolus0.29 ± 0.180.25 ± 0.110.27 ± 0.15
Daily basal pump rates (%)
    One basal rate12 (24)6 (12)18 (18)
    Two basal rates6 (12)7 (14)13 (13)
    Three basal rates14 (28)14 (28)28 (28)
    Four basal rates18 (36)23 (46)41 (41)
Subjects completing study (%)45 (90)46 (92)91 (91)
Withdrawals during treatment (%)5 (10)4 (8)9 (9)
Adverse events (n)000
Noncompliance (%)2 (4)3 (6)5 (5)
Ineffective therapy (%)1 (2)1 (2)2 (2)
Withdrew consent (%)2 (4)02 (2)
  • Data are means ± SD or n (%). Treatment sequence refers to the order of insulin administration in the two treatment periods (i.e., CSII to MDI refers to CSII treatment during period 1 and MDI treatment during period 2).